Gene	Replicate	Mutation	Localization	Aa Change								
BOTH TREATMENTS												
nalD	4, 6, 8	G>T	32	Thr11Asn								
	1	C>G	1126	Leu376Val								
mexB	3	T>G	2300	Val767Gly								
	6	C>T	1345	Leu449Phe								
	8	C>T	1693	Pro565Ser								
	1	G>A	1510	Arg504Cys								
ftsI	5	C>T	1567	Val523Met								
	5	C>T	1511	Arg504His								
	8	C>T	851	Arg284Gln								
clpA	1	Del-A	515	His172fs								
	5	A>G	1634	Tyr545Cys								
		CEFTAZIDIME TREATM	1ENT									
	1	Ins-A	80-81	Glu27fs								
mexR	3	Del-AAT	126-128	Leu43del								
	2	Del-CGGCGGCTT	1305-1313	Phe438_Gly440del								
mpl	2	T>G	371	Val124Gly								
	4	T>G	416	Val139Gly								
orfN	2	Ins-G	138-139	Val50fs								
infB	2	C>T	2407	Val803Ile								
	2	A>C	133	Thr45Pro								
pitA	4	A>C	367	Thr123Pro								
grpE	3	Del-G	39	Glu14fs								
clpP	3	Del-C	365	Gly122fs								
dnaK	3	G>A	1115	Ala372Val								
dacB	4	C>T	343	Gly115Ser								
	CEFTA	ZIDIME/AVIBACTAM T	REATMENT									
dnaJ	5	G>A	1081	Pro361Ser								
pepA	6	C>T	1439	Gly480Asp								
ctpA	6	G>A	971	Ser324Asn								
glnD	6	Ins-G	2466-2467	Asp823fs								
flgF	6	C>A	676	Glu226*								
рст	8	Ins-G	530-531	Arg180fs								
spoT	8	T>C	931	Phe311Leu								

Supplementary Table S1 | Genetic modifications detected in ceftazidime and ceftazidime/avibactam evolved *P. aeruginosa* PA14 populations.

PA14_45870	5	Del-21 pb	712-732	Glu238fs
PA14_45880	7	C>A	159	Met53Ile
	7	G>A	1001	Ser334Leu
PA14_45890	7	G>A	836	Pro279Leu
-	5	G>A	830	Ala277Val
		INTERGENIC MUTAT	IONS	
Between				
<i>PA14_45410</i> and	10	C>T	4044801	-
PA14_45430				
Between 16S				
ribosomal RNA and	12	T>C	6317713	-
PA14_70920				
Between grpE and				
recN	1	T>C	5621761	-
Between <i>mexR</i> and				
mexA	2	C>T	486683	-

Nucleotide location of the mutations and associated amino acid changes. Genetic modifications in intergenic regions are also included, and their locations referred to the nucleotide position in *P. aeruginosa* UCBPP-PA14 reference chromosome (NC\_008463.1). Fs: frameshift. \*: stop codon. Del: deletion. Ins: insertion.

Supplementary Table S2 | Primers used to verify nucleotide modifications detected in whole-genome sequencing.

Gene	Genetic change	Localization	Primer fw (5'-3')	Primer rv (5'-3')									
	SNVs/MNVs												
nalD	C>A	32	AATACTTCGAGTCCGCCC	TTGAGCATCTCGTTGAACAG									
	C>G	1126											
	C>T	1345											
техВ	C>T	1693		CAGGIAIICGCGCAIC									
	T>G	2300	ACGAACCGCAGTACAAGCTG	CGCTCCAGCTTCGGCGAACC									
	C>T	1510											
	G>A	1567	-										
ftsl	G>A	1511	_ AACAAGTGGTCGAGGCCCAG	TGCTGTTCGGTGGCCGT									
	G>A	851	CTGCGCAACGCTCTGCT	AATTGCGCGATACGTCGCGA									
	Del-A	515	TCAAGCAGCAGAGCATCGC	CTACCAGCAGCGGGTTGTT									
clpA	A>G	1634	TCGTTCCTCTTCGCCGGT	CGTTGTTGTCGGTCAGGGT									
	Ins-A	80-81											
mexR	Del-AAT	126-128	ATGAACTACCCCGTGAAT	AAGCTGCGCTGGTCGCT									
	T>G	371											
mpl	T>G	416	GAGCATGTCCTGAACAAGGG	CGGTAATGGACGAACTTCGA									

mpl	Del-CGGCGGCTT	1305-1313	AACCTGGGCTGGGACCT	TCACTCGGCCAGCGCCGC
orfN	Ins-G	138-139	ATGGACGTTCCCAATGCCCG	CCGCCAGAATCAGCAAAACC
infB	C>T	2407	ATCTGCGGGAGAACATCCT	CCTTCTCGAACACTTCGATC
	A>C	133		
<i>pitA</i>	A>C	367	ATGTTCGATCTTTTCAGCGG	CGCGATGTCGATCGCCTT
grpE	Del-G	39	GAACCGTGGAAAGCCGTCCC	AACTTGTGCGCCTTCTCGAC
clpP	Del-C	365	TTGCTGTTCCTGGAGGCTGA	TTCAGACGCTCCTTGATGAA
dnaK	G>A	1115	TGAAGGATGCCGGCCTGGAT	TCTTGTGGACGCTGAAGA
dacB	C>T	343	ACCTATGCCGCCCTGGAAA	CGTCGTTGAATACCGGCAA
dnaJ	G>A	1081	AAGCTGTTCCGCCTGCGCG	ATAAAACCACTCCACGCG
PA14_45870	Del-21 pb	712-732	TCGAGAACAAGCTGCTGCAT	CGGTACTGGTCAGCATCT
рерА	C>T	1439	CTGTTCGACGAATACCAGGA	TCACTTGGCCCGTTCCAG
ctpA	G>A	971	AGGAAGTGGTCAAGGCGCT	TGGATGGAGCGCCCGTT
glnD	Ins-G	2466-2467	ACTCCATCGGCAACAACCC	ACAGCTGCTCGACCAGGGC
flgF	C>A	676	TGAAGCAGATGGAGAAGGG	TTAGCTGATTTGCAAAACCC
PA14_45880	C>A	159	TCGAGGACGAGGCGAAGA	CGAGGAAGGAGAACGGCTTGA
рст	Ins-G	530-531	TTCGTTGGGGCGATGGCTG	TACCGAGTCGAGTACCTGG
spoT	T>C	931	TCAACGAGATCATGGACGTC	CTCGTCGTTGGACTTGTACA

	G>A	1001		
	G>A	836	GCCAACGACCAGTTGTTCAA	ACCGTAGCGACGATCAGGGT
	G>A	830		
		]	LARGE DELETIONS	
Del 1	Del 55009 bp	3387426-3442435	ATGCAACACAGCCAAGTGT	TCAGAACGGTTTGGTCGGCA
			CTGTTCGAGATCGTCGAAGG	TTCGAACTCTTTCTCCTGTA
Del 2	Del 220701 bp	3288650-3509351	ATGCAACACAGCCAAGTGT	TCAGAACGGTTTGGTCGGCA
	Der 220701 op	5200000 5207551	CTGTTCGAGATCGTCGAAGG	TTCGAACTCTTTCTCCTGTA
Del 3	Del 258271 bp	3210297-3468568	GCTTCACCGGTTCGCTGAAG	TCAGTCAATCGCCGCCCG
	r r r		CTGTTCGAGATCGTCGAAGG	TTCGAACTCTTTCTCCTGTA
Del 4	Del 299648 bp	3200274-3499932	GCTTCACCGGTTCGCTGAAG	TCAGTCAATCGCCGCCCG
			CTGTTCGAGATCGTCGAAGG	TTCGAACTCTTTCTCCTGTA
Del 5	Del 442741 bp	3203830-3646571	GCTTCACCGGTTCGCTGAAG	TCAGTCAATCGCCGCCCG
2010	501 1127 11 op	5205050 5010571	GTGGGCAGCATCTACCTGATT	TGATGAGTTCCGGCGCCTT

The locations of SNVs/MNVs are referred to the specific gene, whereas the large deletions locations remit to the nucleotide position in *P. aeruginosa* UCBPP-PA14 reference chromosome (NC\_008463.1).

Treatment	Replicate	5 d	10 d	15 d	20 d	25 d	30 d
	1	20	40	75	100	300	300
CEFTAZIDIME	2	20	60	250	300	400	400
	3	20	40	75	100	150	150
	4	25	40	100	400	300	400
CEFTAZIDIME	5	40	50	150	250	300	400
+	6	15	30	75	250	400	200
AVIBACTAM	7	20	80	200	400	300	400
	8	15	40	50	75	150	150
	9	4	4	4	4	4	4
CONTROLS	10	4	4	4	4	4	4
00111020	11	4	4	4	4	4	4
	12	4	4	4	4	4	4

Supplementary Table S3 | MIC values ( $\mu$ g/ml) obtained by antibiotic dilution for the population replicates during selective pressure with either ceftazidime or ceftazidime/avibactam.

The table shows the liquid MIC values against ceftazidime for each replicate population every five days (the antibiotic concentration was doubled every 5 days). The grey boxes indicate the steps in which these particular replicates were unable to grow. In these situations, the previous ceftazidime concentrations (8MIC in populations 6, 8; and 16MIC in populations 3, 7) were maintained for the rest of the experiment.

Sample	TGC	ТЕТ	ATM	IPM	MEM	CAZ	CIP	LVX	NOR	тов	STR	AMK	GEN	CST	PMB	CHL	ERY	FOF
	15*	30	30	10	10	30	5	5	10	10	25	30	120	50	38.1	50	30	50
PA14 wt	14	16	26	30	21	27	36	31	32	26	22	25	31	17	14	18	13	14
								С	ONTROL	S								
9	12	14	28	30	19	28	37	28	32	22	14/21	23	28	17	14	19	13	13
10	13	15	27	31	17	28	37	29	32	23	20	24	30	17	14	19	12	14
11	13	15	28	32	18	28	38	30	34	24	21	25	29	17	14	18	12	15
12	14	15	28	32	23	28	36	27	32	24	20	25	30	17	14	17	12	16
								CE	FTAZIDI	ME								
1	13	12	0	19	0	0	30	21	26	26	26	29	32	19	15	0	0	27
2	15	12	0	19	0	0	33	26	28	29	29	31	35	19	16	0	0	33
3	15	10	0	25	0	0	31	24	28	25	24	28	32	19	16	0	0	27
4	15	12	0	22	0	0	33	24	28	27	28	31	36	19	16	0	0	31
CEFTAZIDIME + AVIBACTAM																		
5	19	19	0	10	0	0	33	30	31	24	23	28	31	17	15	0	6	27
6	20	22	7	24	0	0	34	30	33	25	22	29	34	18	16	0	0	26
7	23	22	0	9	0	0	38	32	34	23	22	26	33	19	16	0	0	25
8	21	19	0	24	0	0	33	29	28	26	24	30	34	19	16	0	0	27

Supplementary Table S4 | Disk diffusion tests with antibiotics of distinct structural families in the ceftazidime and ceftazidime/avibactam final evolved populations.

The table presents the diameters of halo (mm) in the disk diffusion assays for each replicate population at the end of the experimental evolution. The antibiotics in which halos differed were selected for an E-test assay (Table 1). Indeed, in some cases we chose for the E-test only one or two representative cases of a particular structural family, in order to avoid redundancy. \* The load of each antibiotic disk is indicated in µg. TGC: tigecycline, TET: tetracycline, ATM: aztreonam, IPM: imipenem, MEM: meropenem, CAZ: ceftazidime, CIP: ciprofloxacin, LVX: levofloxacin, NOR: norfloxacin, TOB: tobramycin, STR: streptomycin, AMK: amikacin, GEN: gentamycin, CST: colistin, PMB: polymyxin B, CHL: chloramphenicol, ERY: erythromycin, FOF: fosfomycin.